AzTrials
AzTrials

Severe Acute MalnutritionNCT05614505

Efficacy and Acceptability of RUTFs in Indonesia

A study testing Ready to use therapeutic foods in people with Severe Acute Malnutrition, run by Institut de Recherche pour le Developpement at 1 site in Indonesia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Severe wasting or Severe Acute Malnutrition (SAM) continues to be a major public health problem in Indonesia, affecting more than 2 million children under 5 years old. A new approach to treat SAM is called Community-based management of acute malnutrition (CMAM), which has been designed to maximize the coverage and… Read more about this study

Who is it for?
Ages 6 to 59 months
Conditions the study is for
Severe Acute Malnutrition
What is being tested?
Ready to use therapeutic foods
Could I receive a placebo?
No, everyone receives an active treatment
How many people
300 participants
Where
1 siteIndonesia
Study dates
15 Jul 2021to 25 Jan 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 59 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Children with uncomplicated SAM (WHZ < -3 and/or MUAC <115 mm) qualified for outpatient treatment, or nutritional edema regardless of anthropometry
  • Aged 6-59 months old upon enrolment
  • Pass appetite test
  • Never received in- and outpatient treatment on SAM (including not having consumed RUTF, F75, F100 or special medical specialty food1 in the last two months
  • Willing to participate in the study (parent signed the informed consent)

Who cannot join

  • Body weight < 4.0 kg;
  • Uncontrolled or untreatable systemic opportunistic infection, such as active TB, HIV;
  • Obvious dysmorphic features, general mental health problems (e.g., Down syndrome, etc.), other conditions interfering with normal growth;
  • Participating in another clinical trial;
  • Any congenital disorder that interferes with normal nutrient intake; chronic conditions including but not exclusively disorders of heart, kidney or liver (children to be screened by a physician);
  • SAM with complications requiring hospital treatment (including edema +3);
Show all 9Show fewer
  • Severe anemia (Hb<7g/dL);
  • Is a twin or multiple;
  • Allergy to milk, nuts, legumes and/or antibiotics (Amoxicillin and Ampicillin)

Trial locations and contacts

1 site in 1 country.

Indonesia1 site
  • Savica

    Jakarta

Other trials in Indonesia

About this study

Official title: Efficacy and Acceptability of Ready-to-use Therapeutic Foods (RUTFs) in Indonesia

Severe wasting or Severe Acute Malnutrition (SAM) continues to be a major public health problem in Indonesia, affecting more than 2 million children under 5 years old. A new approach to treat SAM is called Community-based management of acute malnutrition (CMAM), which has been designed to maximize the coverage and successful treatment of children with SAM, by providing Ready to Use Therapeutic Food (RUTF) through out-patient treatment. Since 2019, UNICEF has been working intensively to facilitate the local production of RUTF. This present study aims to assess the acceptability and efficacy of three locally produced RUTFs compared to the standard peanut based RUTF.

The study will be implemented in Bogor district. A total of 300 children with uncomplicated SAM, aged 6-59 months old, meeting the inclusion criteria will be included in the study. This study is designed as a randomized controlled trial. The children will be allocated to one of the five intervention (1 control, 4 experimental) arms. Each child will receive one type of RUTF product for eight consecutive weeks. The ration given to a child will be based on the need for an intake of ~ 170 kcal/kg BW/day. Data will be collected at baseline, at weekly intervals and at exit. The primary outcome of interest for the efficacy study is the relative weight gain of children consuming each of the local RUTFs compared with those consuming the standard RUTF. The primary outcome of the acceptability of the RUTFs will be the amount of product consumed during the eight-week efficacy trial.

Differences in weight and height gain will be analyzed using ANCOVA, controlling for age, gender, food intake, and morbidity. Repeated measurement statistics will be used to analyze differences in growth patterns over the eight-week intervention.

Read the detailed description

OBJECTIVES This study aims to assess the acceptability and efficacy to increase weight and mid upper arm circumference of children aged 6-59 months with severe acute malnutrition (SAM), of three locally produced RUTFs compared to the standard peanut based RUTF. The study will be implemented in Bogor district.

METHODOLOGY Subjects inclusion criteria are reported elsewhere.

Sample Size Calculation If the Indonesian RUTFs fulfil the WHO requirement of an average increase of 4 g/kg BW/day, a sample size of 60 children per group would allow detecting a 20% difference between control and intervention products, assuming a SD of 1.6 g/kg BW, a study design effect of 1.0, a significance of 0.05, a power of 0.80. If children fail to reach this 4 g/kg BW target and only gain 2 g/kg BW/day, the sample size would still allow detection of a 30% difference between the control product and the local product. Since it will be a five-armed intervention, a total of 300 SAM children will be recruited in Bogor district.

Anthropometric and Hemoglobin Measurements Training The training on anthropometric measurements will include repeated practice and comparison of intra- and inter-observer variation to ensure that the field team will have excellent skills in conducting the anthropometric measurements.

Hemoglobin concentration will be measured using Hemocue 201+ device by (or under direct supervision of) a medical doctor, trained in the use of the equipment.

Study Design This study is designed as an individually randomised controlled trial. Parents will be informed of the purpose, risks and benefits of the study and asked to sign the informed consent prior to inclusion of their child in the study.

Each child will be randomly allocated to one of the five intervention arms.

Acceptability Study The primary outcome of the acceptability of the RUTFs will be the amount of product consumed during the 8-week efficacy trial (long-term acceptability). An average consumption of at least 50% of the offered product during the 8-week efficacy trial will be considered acceptable.

The secondary outcome of the acceptability study will be the consumption velocity of the RUTFs during the appetite test (short-term acceptability; see below).

Efficacy Study The primary outcome of interest for the efficacy study is the relative weight gain of children consuming each of the local RUTFs compared with those consuming the standard RUTF. A difference of 20% in weight gain will be considered as physiologically significant.

Randomization Prior to the appetite test, selected children with uncomplicated SAM will be randomized to one of the five intervention arms. The randomization list is made prior to recruitment by a member of the research team not present in the field (FTW). Children randomized to one arm will receive the standard RUTF product, and the other four arms will each receive one of four local RUTFs.

Appetite Test The day after the screening, selected children will need to pass an appetite test prior to enrolment in the intervention.

Design Each child will receive one type of RUTF products for eight consecutive weeks. Data will be collected at baseline, at weekly intervals and at exit. Children who completely refuse to eat the RUTF they have been allocated to for more than 4 days/week, for 2 consecutive weeks, or children who lose or do not gain weight during 2 consecutive weekly visits, and/or develop allergic reaction and clinical symptoms during the course of the study will be dropped from the study and will be referred to the Puskesmas for treatment.

A weekly supply of RUTF will be supplied during each of the weekly check-up visits.

Baseline data General information on socio-economic status of the family, ethnicity, educational level of both parents, household food security, IYCF including 24 h food recall, use of micronutrient supplements (vitamin A, iron, syrup) and supplementary foods (PMT/Local PMT), morbidity history and current morbidity, duration of pregnancy, birth weight, immunization status, deworming, sex and age of the child, will be collected at baseline, in addition to height/length, weight, MUAC and hemoglobin concentration. All data will be recorded using a digital questionnaire on tablet computers.

Monitoring The daily amount of RUTF intake of each child will be recorded by the mother/caregiver in a monitoring book provided by the study team. The field team will visit each child on a weekly basis to monitor the feeding and intake recording by the mother/caregiver, as well as any intra-household sharing of the RUTF.

In addition to the weekly home visits, the PL will maintain regular daily communication with the mothers/caregivers through text messages.

Data Analysis The baseline, monitoring, and endline data will be entered in a digital questionnaire by the field workers. The researcher will extract data from digital questionnaire into SPSS format. Data analyses will be done using SPSS.

Being tested
Ready to use therapeutic foods
Keywords
Ready to use therapeutic food (RUTF), acceptability, local, children, rehabilitation
Medical subject headings
Severe Acute Malnutrition

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ready to use therapeutic foodsDietary supplement

    locally produced therapeutic foods

Study groups in NCT05614505
Study groupRoleWhat they receive
RUTF standardActive comparatorPlumpyNut
Receives: Dietary Supplement: Ready to use therapeutic foods
RUTF local_1ExperimentalSoybean RUTF
Receives: Dietary Supplement: Ready to use therapeutic foods
RUTF local_2ExperimentalMungbean-thick RUTF
Receives: Dietary Supplement: Ready to use therapeutic foods
RUTF local_3ExperimentalMungbean-thin RUTF
Receives: Dietary Supplement: Ready to use therapeutic foods
RUTF local_4ExperimentalWafer RUTF
Receives: Dietary Supplement: Ready to use therapeutic foods

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. short-term acceptability

    Passing the appetite test

    Measured: consumption of at least 50% of RUTF provided in a 30 minute period

  2. long-term acceptability

    drop-out during the intervention

    Measured: Number of children not finishing the 8 week intervention

  3. weight gain over the 8 week intervention

    weight gain (in g) over 8 week intervention

    Measured: weight gain expressed as weight gain (g)/kg body weight per day over the 8 week intervention

Secondary outcomes (5)
  1. recovery rate

    percentage of children having WHZ>-2 and/or MUAC >125 mm

    Measured: from baseline to end of the 8 week intervention

  2. increase in height for age Z scores (HAZ)

    changes in length growth among the intervention arms

    Measured: from baseline to the end of the 8 week intervention

  3. length of stay in the treatment

    Average number of day in treatment to reach recovery or drop-out

    Measured: 8 week intervention or shorter

  4. Morbidity during the intervention

    number of sick days based on the weekly recall data

    Measured: from baseline to 8 week intervention

  5. Perception

    Acceptability of the product by caregivers

    Measured: based on the interview with the caregiver after the 8 week intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Nov 2022
  2. Study start15 Jul 2021
  3. Primary completion15 Dec 2021
  4. Study completion25 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
randomized controlled trial
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
300 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05614505
Sponsor's protocol ID
RUTF_2021_Impact
Status last verified
Nov 2022
First submitted
22 Sep 2021
Last updated
14 Nov 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Yes, IP data will be available upon request

Questions about this trial

What is this clinical trial studying?

A study testing Ready to use therapeutic foods in people with Severe Acute Malnutrition, run by Institut de Recherche pour le Developpement at 1 site in Indonesia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

short-term acceptability (time frame: consumption of at least 50% of RUTF provided in a 30 minute period). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in